Cargando…
Getting TRAIL back on track for cancer therapy
Unlike other members of the TNF superfamily, the TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo2L) possesses the unique capacity to induce apoptosis selectively in cancer cells in vitro and in vivo. This exciting discovery provided the basis for the development of TRAIL-receptor ago...
Autores principales: | Lemke, J, von Karstedt, S, Zinngrebe, J, Walczak, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131183/ https://www.ncbi.nlm.nih.gov/pubmed/24948009 http://dx.doi.org/10.1038/cdd.2014.81 |
Ejemplares similares
-
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
por: Tuthill, Mark H, et al.
Publicado: (2014) -
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
por: von Karstedt, Silvia, et al.
Publicado: (2020) -
Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy
por: Kretz, Anna-Laura, et al.
Publicado: (2018) -
Onto better TRAILs for cancer treatment
por: de Miguel, D, et al.
Publicado: (2016) -
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
por: Lemke, J, et al.
Publicado: (2014)